April 25, 2010
IOM to Advise FDA on Post-Marketing Drug Safety Trials
The Institute of Medicine has been called upon to advise the FDA regarding post-marketing drug safety trials. George Conk at Otherwise has the details.
TrackBack URL for this entry:
Listed below are links to weblogs that reference IOM to Advise FDA on Post-Marketing Drug Safety Trials: